Home > Healthcare > Pharmaceuticals > Finished Drug Form > Generic Oncology Drugs Market
Generic Oncology Drugs Market Size
- Report ID: GMI4425
- Published Date: May 2024
- Report Format: PDF
Generic Oncology Drugs Market Size
Generic Oncology Drugs Market was valued at USD 26.9 billion in 2023 and is estimated to grow at 5.8% CAGR from 2024 to 2032, attributed to the global rise in cancer cases along with factors such as aging demographics, shifts in lifestyle, and environmental influences. According to the latest projections from the World Health Organization's cancer agency, there is an anticipated 77% surge in new cancer cases by 2050, totaling over 35 million cases, compared to the estimated 20 million cases recorded in 2022.
Generic oncology drugs replicate the active pharmaceutical ingredients of branded cancer drugs, providing similar therapeutic outcomes. These drugs are developed post-patent expiry, with rigorous regulatory evaluation to ensure safety, efficacy, and bioequivalence. The generics offer affordable options for treating diverse cancer types, broadening patient access to essential treatments.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Generic Oncology Drugs Market Size in 2023: | USD 26.9 Billion |
| Forecast Period: | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR: | 5.8% |
| 2024 – 2032 Value Projection: | USD 44.1 Billion |
| Historical Data for: | 2021 – 2023 |
| No. of Pages: | 180 |
| Tables, Charts & Figures: | 289 |
| Segments covered: | Drug Type, Indication, Route of Administration, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Generic Oncology Drugs Market Scope
